(GEHC) GE HealthCare Technologies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US36266G1076
Stock: Medical Imaging, Patient Monitoring, Diagnostics, Ultrasound
Total Rating 30
Risk 76
Buy Signal -0.39
| Risk 5d forecast | |
|---|---|
| Volatility | 34.4% |
| Relative Tail Risk | -8.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -43.16 |
| Character TTM | |
|---|---|
| Beta | 1.354 |
| Beta Downside | 1.029 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.35% |
| CAGR/Max DD | -0.04 |
EPS (Earnings per Share)
Revenue
Description: GEHC GE HealthCare Technologies March 04, 2026
GE HealthCare Technologies Inc. (NASDAQ: GEHC) develops, manufactures, and markets products, services, and digital solutions for patient diagnosis, treatment, and monitoring globally. The company operates in the healthcare equipment sector, which is characterized by high research and development costs and regulatory oversight.
GEHCs operations are divided into four segments. The Imaging segment includes molecular imaging, CT, MR, and X-ray systems. The Advanced Visualization Solutions (AVS) segment focuses on ultrasound, image-guided therapies, and interventional solutions. The Patient Care Solutions (PCS) segment provides medical devices, consumables, and digital solutions, including patient monitoring and diagnostic cardiology products. The Pharmaceutical Diagnostics (PDx) segment supplies diagnostic agents, such as contrast media pharmaceuticals and molecular imaging agents, used to enhance diagnostic scans. The companys business model relies on a diverse product portfolio addressing various stages of patient care, from diagnosis to monitoring.
GE HealthCare Technologies Inc. was incorporated in 2022 and is headquartered in Chicago, Illinois. For a deeper dive into GEHCs financial performance and market position, continue your research on ValueRay.
Headlines to watch out for
- Global healthcare spending trends impact equipment and services demand
- Regulatory approvals and product innovation drive market share
- Supply chain disruptions affect manufacturing costs and delivery
- Competition from medical device companies pressures pricing
- Pharmaceutical Diagnostics segment growth boosts overall revenue
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 1.68b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.60 > 1.0 |
| NWC/Revenue: 8.14% < 20% (prev -0.19%; Δ 8.33% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.99b > Net Income 1.68b |
| Net Debt (5.49b) to EBITDA (3.58b): 1.53 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (460.3m) vs 12m ago 0.28% < -2% |
| Gross Margin: 43.49% > 18% (prev 0.42%; Δ 4.31k% > 0.5%) |
| Asset Turnover: 56.00% > 50% (prev 59.45%; Δ -3.44% > 0%) |
| Interest Coverage Ratio: 5.78 > 6 (EBITDA TTM 3.58b / Interest Expense TTM 450.0m) |
Altman Z'' 1.40
| A: 0.04 (Total Current Assets 10.70b - Total Current Liabilities 9.11b) / Total Assets 36.91b |
| B: 0.14 (Retained Earnings 5.28b / Total Assets 36.91b) |
| C: 0.07 (EBIT TTM 2.60b / Avg Total Assets 35.00b) |
| D: 0.15 (Book Value of Equity 3.90b / Total Liabilities 26.31b) |
| Altman-Z'' Score: 1.40 = BB |
Beneish M -3.16
| DSRI: 0.91 (Receivables 3.96b/4.38b, Revenue 19.60b/19.67b) |
| GMI: 0.96 (GM 43.49% / 41.70%) |
| AQI: 0.99 (AQ_t 0.63 / AQ_t-1 0.64) |
| SGI: 1.00 (Revenue 19.60b / 19.67b) |
| TATA: -0.01 (NI 1.68b - CFO 1.99b) / TA 36.91b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of GEHC shares?
As of March 15, 2026, the stock is trading at USD 72.65 with a total of 2,491,037 shares traded.
Over the past week, the price has changed by -4.71%, over one month by -11.91%, over three months by -16.17% and over the past year by -12.95%.
Over the past week, the price has changed by -4.71%, over one month by -11.91%, over three months by -16.17% and over the past year by -12.95%.
Is GEHC a buy, sell or hold?
GE HealthCare Technologies has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy GEHC.
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GEHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.1 | 28.1% |
| Analysts Target Price | 93.1 | 28.1% |
GEHC Fundamental Data Overview March 13, 2026
P/E Trailing = 15.967
P/E Forward = 14.3678
P/S = 1.6053
P/B = 3.1936
P/EG = 1.7317
Revenue TTM = 19.60b USD
EBIT TTM = 2.60b USD
EBITDA TTM = 3.58b USD
Long Term Debt = 9.49b USD (from longTermDebt, last quarter)
Short Term Debt = 508.0m USD (from shortTermDebt, last quarter)
Debt = 10.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.49b USD (from netDebt column, last quarter)
Enterprise Value = 38.60b USD (33.11b + Debt 10.00b - CCE 4.51b)
Interest Coverage Ratio = 5.78 (Ebit TTM 2.60b / Interest Expense TTM 450.0m)
EV/FCF = 25.63x (Enterprise Value 38.60b / FCF TTM 1.51b)
FCF Yield = 3.90% (FCF TTM 1.51b / Enterprise Value 38.60b)
FCF Margin = 7.68% (FCF TTM 1.51b / Revenue TTM 19.60b)
Net Margin = 8.57% (Net Income TTM 1.68b / Revenue TTM 19.60b)
Gross Margin = 43.49% ((Revenue TTM 19.60b - Cost of Revenue TTM 11.07b) / Revenue TTM)
Gross Margin QoQ = 54.34% (prev 38.69%)
Tobins Q-Ratio = 1.05 (Enterprise Value 38.60b / Total Assets 36.91b)
Interest Expense / Debt = 1.03% (Interest Expense 103.0m / Debt 10.00b)
Taxrate = 26.73% (54.0m / 202.0m)
NOPAT = 1.90b (EBIT 2.60b * (1 - 26.73%))
Current Ratio = 1.18 (Total Current Assets 10.70b / Total Current Liabilities 9.11b)
Debt / Equity = 0.96 (Debt 10.00b / totalStockholderEquity, last quarter 10.38b)
Debt / EBITDA = 1.53 (Net Debt 5.49b / EBITDA 3.58b)
Debt / FCF = 3.65 (Net Debt 5.49b / FCF TTM 1.51b)
Total Stockholder Equity = 9.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.80% (Net Income 1.68b / Total Assets 36.91b)
RoE = 17.11% (Net Income TTM 1.68b / Total Stockholder Equity 9.82b)
RoCE = 13.46% (EBIT 2.60b / Capital Employed (Equity 9.82b + L.T.Debt 9.49b))
RoIC = 9.70% (NOPAT 1.90b / Invested Capital 19.65b)
WACC = 8.55% (E(33.11b)/V(43.11b) * Re(10.90%) + D(10.00b)/V(43.11b) * Rd(1.03%) * (1-Tc(0.27)))
Discount Rate = 10.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.25%
[DCF] Terminal Value 75.64% ; FCFF base≈1.52b ; Y1≈1.48b ; Y5≈1.47b
[DCF] Fair Price = 39.70 (EV 23.58b - Net Debt 5.49b = Equity 18.09b / Shares 455.7m; r=8.55% [WACC]; 5y FCF grow -4.08% → 2.90% )
EPS Correlation: -8.91 | EPS CAGR: -10.47% | SUE: -1.21 | # QB: 0
Revenue Correlation: 56.90 | Revenue CAGR: 1.98% | SUE: 1.11 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.17 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+5 | Analysts=16
EPS current Year (2026-12-31): EPS=5.06 | Chg7d=-0.000 | Chg30d=+0.034 | Revisions Net=+4 | Growth EPS=+10.3% | Growth Revenue=+4.9%
EPS next Year (2027-12-31): EPS=5.57 | Chg7d=+0.000 | Chg30d=-0.004 | Revisions Net=+8 | Growth EPS=+10.0% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: +0.56 (7 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.6% (Discount Rate 10.9% - Earnings Yield 6.3%)
[Growth] Growth Spread = +0.3% (Analyst 5.0% - Implied 4.6%)
P/E Forward = 14.3678
P/S = 1.6053
P/B = 3.1936
P/EG = 1.7317
Revenue TTM = 19.60b USD
EBIT TTM = 2.60b USD
EBITDA TTM = 3.58b USD
Long Term Debt = 9.49b USD (from longTermDebt, last quarter)
Short Term Debt = 508.0m USD (from shortTermDebt, last quarter)
Debt = 10.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.49b USD (from netDebt column, last quarter)
Enterprise Value = 38.60b USD (33.11b + Debt 10.00b - CCE 4.51b)
Interest Coverage Ratio = 5.78 (Ebit TTM 2.60b / Interest Expense TTM 450.0m)
EV/FCF = 25.63x (Enterprise Value 38.60b / FCF TTM 1.51b)
FCF Yield = 3.90% (FCF TTM 1.51b / Enterprise Value 38.60b)
FCF Margin = 7.68% (FCF TTM 1.51b / Revenue TTM 19.60b)
Net Margin = 8.57% (Net Income TTM 1.68b / Revenue TTM 19.60b)
Gross Margin = 43.49% ((Revenue TTM 19.60b - Cost of Revenue TTM 11.07b) / Revenue TTM)
Gross Margin QoQ = 54.34% (prev 38.69%)
Tobins Q-Ratio = 1.05 (Enterprise Value 38.60b / Total Assets 36.91b)
Interest Expense / Debt = 1.03% (Interest Expense 103.0m / Debt 10.00b)
Taxrate = 26.73% (54.0m / 202.0m)
NOPAT = 1.90b (EBIT 2.60b * (1 - 26.73%))
Current Ratio = 1.18 (Total Current Assets 10.70b / Total Current Liabilities 9.11b)
Debt / Equity = 0.96 (Debt 10.00b / totalStockholderEquity, last quarter 10.38b)
Debt / EBITDA = 1.53 (Net Debt 5.49b / EBITDA 3.58b)
Debt / FCF = 3.65 (Net Debt 5.49b / FCF TTM 1.51b)
Total Stockholder Equity = 9.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.80% (Net Income 1.68b / Total Assets 36.91b)
RoE = 17.11% (Net Income TTM 1.68b / Total Stockholder Equity 9.82b)
RoCE = 13.46% (EBIT 2.60b / Capital Employed (Equity 9.82b + L.T.Debt 9.49b))
RoIC = 9.70% (NOPAT 1.90b / Invested Capital 19.65b)
WACC = 8.55% (E(33.11b)/V(43.11b) * Re(10.90%) + D(10.00b)/V(43.11b) * Rd(1.03%) * (1-Tc(0.27)))
Discount Rate = 10.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.25%
[DCF] Terminal Value 75.64% ; FCFF base≈1.52b ; Y1≈1.48b ; Y5≈1.47b
[DCF] Fair Price = 39.70 (EV 23.58b - Net Debt 5.49b = Equity 18.09b / Shares 455.7m; r=8.55% [WACC]; 5y FCF grow -4.08% → 2.90% )
EPS Correlation: -8.91 | EPS CAGR: -10.47% | SUE: -1.21 | # QB: 0
Revenue Correlation: 56.90 | Revenue CAGR: 1.98% | SUE: 1.11 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.17 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+5 | Analysts=16
EPS current Year (2026-12-31): EPS=5.06 | Chg7d=-0.000 | Chg30d=+0.034 | Revisions Net=+4 | Growth EPS=+10.3% | Growth Revenue=+4.9%
EPS next Year (2027-12-31): EPS=5.57 | Chg7d=+0.000 | Chg30d=-0.004 | Revisions Net=+8 | Growth EPS=+10.0% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: +0.56 (7 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.6% (Discount Rate 10.9% - Earnings Yield 6.3%)
[Growth] Growth Spread = +0.3% (Analyst 5.0% - Implied 4.6%)